Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series
作者: Romain AltweggRoman CombesDavid LaharieVictor De LedinghenSylvie RadenneFilomena ContiOlivier ChazouilleresChristophe DuvouxJérôme DumortierVincent LeroyXavier TretonFrançois DurandSébastien DharancyMaria NachuryFélix GoutorbeGéraldine LamblinLucile BoivineauLaurent Peyrin-BirouletGeorges-Philippe Pageaux
作者单位: 1University Hospital of St Eloi, Department of Hepatology and Gastroenterology, Montpellier, France
2University Hospital of Bordeaux, Haut-Leveque Hospital, Hepato-Gastroenterology, Bordeaux, France
3University Hospital, Croix Rousse, HCL, Lyon, France
4University Hospital of Saint Antoine, APHP, Hepato-Gastroenterology, Paris, France
5University Hospital of Henri Mondor, APHP, Hepato-Gastroenterology, Creteil, France
6University Hospital, Edouard Herriot, HCL, Lyon, France
7University Hospital of Grenoble, Hepato-Gastroenterology, Grenoble, France
8University Hospital of Beaujon, APHP, Gastroenterology, Clichy, France
9University Hospital of Lille, Hepato-Gastroenterology, Lille, France
10University Hospital of Clermont-Ferrand, Hepato-Gastroenterology, Clermont-Ferrand, France
11Inserm U954 and Department of Gastroenterology, Nancy University Hospital of Nancy, Lorraine University, Nancy, France
刊名: Digestive and Liver Disease, 2018
来源数据库: Elsevier Journal
DOI: 10.1016/j.dld.2018.02.014
关键词: Anti-TNF alphaInflammatory bowel diseaseLiver transplantation
原始语种摘要: Abstract(#br)Background(#br)There is a lack of consensus regarding the treatment of inflammatory bowel disease (IBD) after liver transplantation (LT) forprimary sclerosing cholangitis (PSC).(#br)Aim(#br)To investigate the safety and effectiveness of anti-TNF therapy in patients with IBD after a LT for PSC.(#br)Methods(#br)We reviewed the medical files of all of the IBD patients who underwent a LT for PSC and who were treated with anti-TNF therapy at 23 French liver transplantation centers between 1989 and 2012.(#br)Results(#br)Eighteen patients (12 with ulcerative colitis and 6 who had Crohn’s disease) were recruited at 9 LT centers. All of these patients received infliximab or adalimumab following their LT, and the median duration of their anti-TNF treatment was 10.4 months. The most...
全文获取路径: Elsevier  (合作)
影响因子:3.162 (2012)

  • follow 
  • treatment 处理
  • cholangitis 胆管炎
  • effective 有效的
  • liver 
  • treating 处理
  • bowel 
  • safety 安全
  • achieved 获得的
  • PSC Preset Course